• IDontHavePantsOn@lemm.ee
    link
    fedilink
    arrow-up
    26
    ·
    7 months ago

    Basically every time a psilocybin study is conducted for use in mental health applications it’s found to be beneficial. It’s just that the DEA doesn’t give a fuck and refuse to change the schedule of the drug even with countless studies showing it’s effectiveness, as well as countless doctors, researchers, and institutes recommending they reduce psilocybin to schedule III.

    Also, we all know what they were doing with that thumbnail.

      • IDontHavePantsOn@lemm.ee
        link
        fedilink
        arrow-up
        4
        arrow-down
        1
        ·
        7 months ago

        I’ll listen to the podcast because I’m sure there’s info in it that will be new to me, but I do know drug scheduling creates a purgatory that makes substances difficult to research. When the scheduling means that it can’t be produced in amounts to create meaningful clinical studies, the “drugs with no currently accepted medical use” definition is difficult to get out of.

        To add on to that, if John Hopkins research labs, the same one that came up with CPR, water purification, and genetic engineering, thinks psilocybin has medical use and merit, I believe them.

  • Addv4@kbin.social
    link
    fedilink
    arrow-up
    21
    ·
    7 months ago

    While I’m all for descheduling psilocybin (and decriminalizing it as well), it should be noted that this was a very small sample size study (15 people) and I’ve heard anecdotal warnings to not take shrooms if bipolar or schizophrenic for years, as there might be a slight risk of psychosis.

    • Fubber Nuckin'@lemmy.world
      link
      fedilink
      arrow-up
      18
      ·
      7 months ago

      You also have to take into account the setting the test was administered in. The participants underwent therapy before, during, and after the treatment. Being in a safe space with immediate access to mental health professionals probably decreases the risks substantially.